Table 2 Correlation between MAP-tau expression and clinicopathologic variables in the Yale University cohort
| Â | MAP-tau expression | Â | |
|---|---|---|---|
Variable | Low (%) (AQUA score < 462) | High (%) (AQUA score > 462) | P* |
Menopausal status | Â | Â | Â |
   Premenopausal | 108 (22.8) | 31 (6.5) | 0.734 |
   Postmenopausal | 265 (55.9) | 70 (14.8) |  |
Tumor size | Â | Â | Â |
   < 2 cm | 128 (29.1) | 31 (7.1) | 0.535 |
   2-5 cm | 155 (35.2) | 50 (11.4) |  |
   > 5 cm | 59 (13.4) | 17 (3.9) |  |
Nuclear grade | Â | Â | Â |
   Small/uniform nuclei | 60 (13.4) | 15 (3.4) | 0.225 |
   Intermediate nuclei | 182 (40.6) | 61 (13.6) |  |
   Large nuclei | 107 (23.9) | 23 (5.1) |  |
Nodal status | Â | Â | Â |
   Node positive | 199 (41.8) | 47 (9.9) | 0.201 |
   Node negative | 175 (36.8) | 55 (11.6) |  |
ER | Â | Â | Â |
   Negative | 227 (48.6) | 38 (8.1) | < 0.0001 |
   Positive | 140 (29.9) | 62 (13.3) |  |
PR | Â | Â | Â |
   Negative | 240 (52.4) | 31 (6.8) | < 0.0001 |
   Positive | 120 (26.2) | 67 (14.6) |  |
HER2 | Â | Â | Â |
   Negative | 283 (61.3) | 88 (19.1) | 0.010 |
   Positive | 80 (17.3) | 11 (2.4) |  |